Advertisement

Pharmacy World and Science

, Volume 26, Issue 4, pp 238–241 | Cite as

Gemcitabine plus vinorelbine chemotherapy regimens: a pharmacokinetic study of alternate administration sequences

  • Luigi CattelEmail author
  • Mario Airoldi
  • Roberto Passera
  • Elga Cagliero
  • Barbara Stella
  • Franca Goffredo
Article

Abstract

Methods: Enrolled in this study were 31 patients with different advanced carcinoma: 9 patients were given GEM (1 h i.v. infusion, 1000 mg/m2) followed after 5 min by VNR (10 min i.v. infusion, 25 mg/m2) (GEM-VNR sequence); 17 patients received VNR followed by GEM (VNR-GEM sequence), at the same doses and with the same infusion period; as a control group (GEM), 5 patients were given only single-agent gemcitabine (1 h i.v. infusion, 1000 mg/m2).

Results: GEM serum levels showed higher Cmax and AUCtot in the VNR-GEM protocol than in the GEM-VNR and GEM groups. The GEM pharmacokinetic profile in both schedules showed biphasic elimination, as in monotherapy. VNR concentration/time curves showed rapid plasma clearance and wide interpatient variability in both sequences. VNR Cmaxwas higher in the VNR-GEM group than in GEM-VNR, while VNR AUCtot and Cltot did not differ significantly in the two sequences.

Conclusions: Some pk-values were altered for both GEM and VNR, following the two alternate protocols. A possible rationale for this behaviour is that VNR and GEM may influence each other during liver elimination extraction and metabolism.

Breast cancer Chemotherapy Gemcitabine Head/neck cancer Hodgkin’s lymphoma HPLC analysis Non-small cell lung cancer Pharmacokinetics Vinorelbine 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Storniolo AM, Allerheiligen S, Pearce HL. Preclinical, pharmacologic and phase I studies of gemcitabine. Semin Oncol 1997; 24:2–7.Google Scholar
  2. 2.
    Eli Lilly and Co. Summary of product characteristics: gemcitabine. UK prescribing information. Eli Lilly 1997.Google Scholar
  3. 3.
    Gregory RK, Smith IE. Vinorelbine: a clinical review. Br J Cancer 2000; 82: 1907–13.Google Scholar
  4. 4.
    Rahmani R, Bruno R, Iliadis A et al. Clinical pharmacokinetics of the antitumor drug navelbine. Cancer Res 1987; 47: 5796–9Google Scholar
  5. 5.
    Chen YM, Peng JW, Perng RP et al. A multicenter phase II study of gemcitabine and vinorelbine in patients with advanced stage IIIB/IV non-small cell lung cancer. Proc Am Soc Clin Oncol 1999; 18: 481 (Abstract).Google Scholar
  6. 6.
    Cattel L, Recalenda V, Airoldi M et al. A sequence-dependent combination of docetaxel and vinorelbine: pharmacokinetic interactions. Farmaco 2001; 56: 779–84.Google Scholar
  7. 7.
    Freeman KB, Anliker S, HamiltonM et al. Validated assays for the determination of gemcitabine in human plasma and urine using high-performance liquid chromatography with ultraviolet detection. J Chromatogr B 1995; 665: 171–81.Google Scholar
  8. 8.
    Robieux I, Vitali V, Aita P et al. Sensitive high-performance liquid chromatographic method with fluorescence detection for measurement of vinorelbine plasma concentration. J Chromatogr B 1996; 675: 183–7.Google Scholar
  9. 9.
    Perez-Manga G, Lluch A, Alba E et al. Gemcitabine in combination with doxorubicin in advanced breast cancer: final results of a phase II pharmacokinetic trial. J Clin Oncol 2000; 18: 2545–52.Google Scholar
  10. 10.
    Sorio R, Robieux I, Galligioni E et al. Pharmacokinetics and tolerance of vinorelbine in elderly patients with metastatic breast cancer. Eur J Cancer 1997; 33: 301–3.Google Scholar

Copyright information

© Kluwer Academic Publishers 2004

Authors and Affiliations

  • Luigi Cattel
    • 1
    • 1
    Email author
  • Mario Airoldi
    • 2
  • Roberto Passera
    • 1
  • Elga Cagliero
    • 3
  • Barbara Stella
    • 1
  • Franca Goffredo
    • 1
  1. 1.Dipartimento di Scienza e Tecnologia del FarmacoUniversità di TorinoTorinoItaly
  2. 2.Dipartimento di Oncologia MedicaOspedale San Giovanni Battista Antica SedeTorinoItaly
  3. 3.Servizio di FarmaciaIstituto per la Ricerca e la Cura del CancroTorinoItaly

Personalised recommendations